KRAS and non-small cell lung carcinoma: In the KEYNOTE-042 study, patients with KRAS G12C-positive NSCLC had similar ORR, PFS, and OS compared with the overall cohort of patients with unspecified KRAS-mutated NSCLC while being treated with pembrolizumab monotherapy.37